Company
Headquarters: Chongqing, China
Employees: 3,782
CN¥9.37 Billion
CNY as of July 1, 2025
US$1.31 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Porton Pharma Solutions Ltd. manufactures and supplies small molecule active pharmaceutical ingredients and drug intermediates, dosage forms, and biologics to the pharmaceutical companies. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. Porton Pharma Solutions Ltd. was founded in 2005 and is headquartered in Chongqing, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥3.14 B |
| EBITDA | CN¥244.9 M |
| Gross Profit TTM | CN¥806.2 M |
| Profit Margin | -6.29% |
| Operating Margin | 0.99% |
| Quarterly Revenue Growth | 18.20% |
Porton Pharma Solutions Ltd has the following listings and related stock indices.
Stock: SZSE: 300363 wb_incandescent